科研成果详情

题名Withaferin A suppressed hepatocellular carcinoma progression through inducing IGF2BP3/FOXO1/JAK2/STAT3 pathway-mediated ROS production
作者
发表日期2023-08-17
发表期刊Immunopharmacology and immunotoxicology   影响因子和分区
语种英语
原始文献类型Journal Article
关键词FOXO1 IGF2BP3 JAK2/STAT3 signaling ROS Withaferin A hepatocellular carcinoma
其他关键词FOXO1 ; PROLIFERATION ; CELLS
摘要Objective: This study aimed to investigate the underlying molecular mechanisms of Withaferin A (WA) in hepatocellular carcinoma (HCC).Materials and Methods: The gene and protein expression were analyzed using RT-qPCR and western blot, respectively. The proliferation of HCC cells was evaluated by CCK-8 assays. The migrative ability of HCC cells was measured by transwell assays.Results: We revealed that WA suppressed the proliferation and migration of HCC cells and inhibited IGF2BP3 (insulin like growth factor 2 mRNA binding protein 3) expression. IGF2BP3 abundance reversed the reactive oxygen species (ROS) accumulation and suppression of HCC cell proliferation and migration induced by WA. Besides, IGF2BP3 suppressed ROS production to promote the growth and migration of HCC cells. Furthermore, we found that IGF2BP3 exerted its tumor-promotive and ROS-suppressive effect on HCC cells by regulating the expression of FOXO1 (forkhead box O1). In addition, IGF2BP3-stimulated activation of JAK2 (Janus kinase 2)/STAT3 (signal transducer and activator of transcription 3) phosphorylation effectively decreased the transcription of FOXO1. FOXO1 abundance decreased the phosphorylation of JAK2 and STAT3 by increasing ROS level, forming a feedback loop for the inhibition of JAK2/STAT3 signaling activated by IGF2BP3.Conclusions: WA-induced ROS inhibited HCC cell growth and migration through the inhibition of IGF2BP3 to deactivate JAK2/STAT3 signaling, resulting in increased FOXO1 expression to further stimulate ROS production and inhibit JAK2/STAT3 signaling
资助项目Medical and Health Research Project of Zhejiang Province [2022KY353]; Young Talent Development Plan of Changzhou Health Commission [CZQM2020049]; Applied Basic Research of Changzhou Technology Bureau [CJ20220118]
出版者TAYLOR & FRANCIS LTD
ISSN0892-3973
EISSN1532-2513
卷号46期号:1页码:40-48
DOI10.1080/08923973.2023.2247552
页数9
WOS类目Immunology ; Pharmacology & Pharmacy ; Toxicology
WOS研究方向Immunology ; Pharmacology & Pharmacy ; Toxicology
WOS记录号WOS:001059564400001
收录类别PUBMED ; SCIE ; SCOPUS
URL查看原文
PubMed ID37671837
SCOPUSEID2-s2.0-85169911861
通讯作者地址[Yang, Yu]Department of Hepatopancreatobiliary Surgery,The Third Affiliated Hospital of Soochow University,185 Juqian Street, Jiangsu,Changzhou,213000,China
Scopus学科分类Immunology and Allergy;Immunology;Toxicology;Pharmacology
引用统计
文献类型期刊论文
条目标识符https://kms.wmu.edu.cn/handle/3ETUA0LF/182773
专题其他_附属第三医院(瑞安市人民医院)
通讯作者Yang, Yu
作者单位
1.Department of Hepatobiliary Surgery,The Third Affiliated Hospital of Wenzhou Medical University,Wenzhou,China;
2.Department of Hepatopancreatobiliary Surgery,The Third Affiliated Hospital of Soochow University,Changzhou,China
第一作者单位其他_附属第三医院(瑞安市人民医院)
第一作者的第一单位其他_附属第三医院(瑞安市人民医院)
推荐引用方式
GB/T 7714
Li, Jinhai,Ge, Mengchen,Deng, Pengcheng,et al. Withaferin A suppressed hepatocellular carcinoma progression through inducing IGF2BP3/FOXO1/JAK2/STAT3 pathway-mediated ROS production[J]. Immunopharmacology and immunotoxicology,2023,46(1):40-48.
APA Li, Jinhai, Ge, Mengchen, Deng, Pengcheng, Wu, Xinquan, Shi, Longqing, & Yang, Yu. (2023). Withaferin A suppressed hepatocellular carcinoma progression through inducing IGF2BP3/FOXO1/JAK2/STAT3 pathway-mediated ROS production. Immunopharmacology and immunotoxicology, 46(1), 40-48.
MLA Li, Jinhai,et al."Withaferin A suppressed hepatocellular carcinoma progression through inducing IGF2BP3/FOXO1/JAK2/STAT3 pathway-mediated ROS production".Immunopharmacology and immunotoxicology 46.1(2023):40-48.

条目包含的文件

条目无相关文件。
个性服务
查看访问统计
谷歌学术
谷歌学术中相似的文章
[Li, Jinhai]的文章
[Ge, Mengchen]的文章
[Deng, Pengcheng]的文章
百度学术
百度学术中相似的文章
[Li, Jinhai]的文章
[Ge, Mengchen]的文章
[Deng, Pengcheng]的文章
必应学术
必应学术中相似的文章
[Li, Jinhai]的文章
[Ge, Mengchen]的文章
[Deng, Pengcheng]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。